 NEW YORK, NY PR Newswire Hoth Therapeutics, Inc. NASDAQ: HOTH , a biopharmaceutical company, today announced that is has received Human Research Ethics Committee HREC clearance to commence cohort 2 of the Phase 1 clinical trial of BioLexa Lotion for the treatment of mild to moderate atopic dermatitis in Australia. BioLexa Trial Design: 